Skip to main content

Table 3 Multivariate logistic regression models to examine the effect of cytomegalovirus diseases on the development of moderate-to-severe dementia according to sex and age distribution

From: Association between cytomegalovirus end-organ diseases and moderate-to-severe dementia: a population-based cohort study

Type of dementia

Subgroups

CMV diseases

Number of participants

Events

IRa

OR (95% CI)

P-value

Model 1

Model 2

Model 3

All

Sex

M

No

1950

42

5.20

1 (Ref.)

1 (Ref.)

1 (Ref.)

0.648

Yes

390

17

11.45

2.19 (1.25–3.85)

2.26 (1.27–3.99)

2.02 (1.09–3.59)

F

No

1485

63

10.50

1 (Ref.)

1 (Ref.)

1 (Ref.)

Yes

297

21

19.46

1.86 (1.13–3.04)

1.91 (1.09–3.12)

1.93 (1.14–3.23)

Age

40–59

No

2030

3

0.35

1 (Ref.)

1 (Ref.)

1 (Ref.)

0.025

Yes

406

7

4.28

12.31 (3.18–47.60)

12.47 (3.14–48.76)

11.68 (2.45–49.37)

60–79

No

1260

62

12.47

1 (Ref.)

1 (Ref.)

1 (Ref.)

Yes

252

21

24.48

1.97 (1.20–3.24)

2.00 (1.21–3.34)

1.83 (1.07–3.15)

≥ 80

No

145

40

86.74

1 (Ref.)

1 (Ref.)

1 (Ref.)

Yes

29

10

145.71

1.62 (0.81–3.24)

1.38 (0.69–2.88)

1.31 (0.49–2.83)

AD

Sex

M

No

1950

29

3.59

1 (Ref.)

1 (Ref.)

1 (Ref.)

0.197

Yes

390

13

8.76

2.44 (1.27–4.69)

2.47 (1.25–4.72)

2.37 (1.21–4.62)

F

No

1485

48

8.00

1 (Ref.)

1 (Ref.)

1 (Ref.)

Yes

297

10

9.27

1.17 (0.59–2.31)

1.22 (0.60–2.45)

1.28 (0.61–2.59)

Age

40–59

No

2030

2

0.23

1 (Ref.)

1 (Ref.)

1 (Ref.)

0.037

Yes

406

4

2.44

10.57 (1.94–57.69)

10.62 (1.88–58.76)

13.59 (2.14–86.26)

60–79

No

1260

46

9.25

1 (Ref.)

1 (Ref.)

1 (Ref.)

Yes

252

14

16.32

1.80 (0.99–3.27)

1.89 (1.01–3.45)

1.77 (0.99–3.30)

≥ 80

No

145

29

62.89

1 (Ref.)

1 (Ref.)

1 (Ref.)

Yes

29

5

72.85

1.14 (0.44–2.96)

1.02 (0.36–2.70)

1.01 (0.33–2.76)

VaD

Sex

M

No

1950

7

0.87

1 (Ref.)

1 (Ref.)

1 (Ref.)

0.243

Yes

390

2

1.35

1.52 (0.32–7.32)

1.58 (0.29–7.90)

1.27 (0.19–6.54)

F

No

1485

5

0.83

1 (Ref.)

1 (Ref.)

1 (Ref.)

Yes

297

5

4.63

5.47 (1.58–18.88)

5.42 (1.47–17.87)

4.31 (1.08–16.51)

Age

40–59

No

2030

1

0.12

1 (Ref.)

1 (Ref.)

1 (Ref.)

0.781

Yes

406

1

0.61

5.21 (0.33–83.36)

5.24 (0.28–78.93)

1.18 (0.05–23.31)

60–79

No

1260

7

1.41

1 (Ref.)

1 (Ref.)

1 (Ref.)

Yes

252

3

3.50

2.40 (0.62–9.26)

2.44 (0.60–9.52)

1.83 (0.36–7.69)

≥ 80

No

145

4

8.67

1 (Ref.)

1 (Ref.)

1 (Ref.)

Yes

29

3

43.71

4.66 (1.04–20.90)

4.34 (0.82–17.59)

5.29 (0.78–31.74)

Others

Sex

M

No

1950

6

0.74

1 (Ref.)

1 (Ref.)

1 (Ref.)

0.642

Yes

390

2

1.35

1.80 (0.36–8.92)

1.82 (0.23–9.43)

1.56 (0.21–7.96)

F

No

1485

10

1.67

1 (Ref.)

1 (Ref.)

1 (Ref.)

Yes

297

6

5.56

3.28 (1.19–9.03)

3.15 (1.07–8.77)

3.15 (1.05–9.23)

Age

40–59

No

2030

0

0.0

–

–

–

–

Yes

406

2

1.22

–

–

–

60–79

No

1260

9

1.81

1 (Ref.)

1 (Ref.)

1 (Ref.)

Yes

252

4

4.66

2.52 (0.77–8.17)

2.37 (0.65–8.37)

2.41 (0.68–8.29)

≥ 80

No

145

7

15.18

1 (Ref.)

1 (Ref.)

1 (Ref.)

Yes

29

2

29.14

1.74 (0.36–8.41)

1.19 (0.20–6.21)

1.31 (0.23–7.03)

  1. Data are expressed as number or OR (95% CI). Events indicate the new-onset moderate-to-severe dementia. Model 1, non-adjusted; Model 2, age-, sex-, low income status, and BMI-adjusted; Model 3, age-, sex-, low income status-, BMI-, SOT recipients-, HSCT recipients-, malignant neoplasms-, ESRD on dialysis-, NIDDM-, hypertension-, and dyslipidaemia-adjusted
  2. Abbreviations; AD Alzheimer’s disease, BMI body mass index, CI confidence interval, CMV cytomegalovirus, ESRD end-stage renal disease, F female, HSCT haematopoietic stem cell transplantation, IR incidence rate, M male, No number of patients, NIDDM non-insulin-dependent diabetes mellitus, OR odds ratio, Ref. reference, SOT solid organ transplantation; VaD vascular dementia
  3. aPer 1000 person-years
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us